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Objective: Non‐invasive prenatal testing (NIPT) detects placental chromosome
aberrations. When amniocentesis reveals a normal karyotype, confined placental
mosaicism (CPM) may be assumed. In order to confirm this, placental cytogenetic
studies were performed.
Method: NIPT was conducted in the course of the DutchTRIDENT study. Placentas
of 10 cases with NIPT results indicating an autosomal trisomy and showing a normal
(N = 9) or low mosaic karyotype (N = 1) in amniotic fluid (AF) were investigated. The
cytotrophoblast as well as the mesenchymal core of two to four placental chorionic
villi biopsies were studied with single nucleotide polymorphism (SNP) array. Clinical
outcome data were collected.
Results: In 10/10 cases, CPM was proven. In 3/10 cases trisomy/uniparental
disomy (UPD)/biparental disomy (BPD) mosaicism was discovered. In 2/3 cases, all
three cell lines were present in the placenta, whereas BPD was found in AF. In 1/3
cases trisomy 22/UPD22 was present in AF while trisomy 22/BPD22 mosaicism
was found in the placenta. Five of 10 pregnancies were affected with pre‐eclampsia,
low birth weight, preterm delivery, and/or congenital malformations.
Conclusion: The presence of trisomy/UPD/BPD mosaicism in 3/10 cases that we
investigated proves that trisomic zygote rescue may involve multiple rescue events
during early embryogenesis. UPD mosaicism, when present in crucial fetal tissues,
may explain the abnormal phenotype in undiagnosed cases.- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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What's already known about this topic?
• Trisomic zygote rescue is the main mechanism for
uniparental disomy (UPD) formation.
• Confined placental mosaicism (CPM) is the major source
of discordant NIPT results.
• CPM is associated with a risk for adverse pregnancy
outcome.
What does this study add?
• Trisomic zygote rescue may involve multiple rescue
events based on the co‐occurrence of a trisomy‐,
UPD‐ and BPD‐cell line in half of the rescued cases as
revealed by placental studies.
2 VAN OPSTAL ET AL.1 | INTRODUCTION
It is now recognized that confined placental mosaicism (CPM) with the
chromosome aberration restricted to the placenta and absent in the
fetus is the major origin of discordant results of non‐invasive prenatal
testing (NIPT).1 Those who perform extended NIPT, investigating all
chromosomes, already discovered that chromosome aberrations typi-
cally involved in CPM, like trisomy 16 and trisomy 7, are also commonly
found with NIPT.1-7 The trisomies involved in CPM may have a mitotic
as well as meiotic origin. If meiotic, the normal fetal karyotype results
from trisomic zygote rescue.8,9 If one of the chromosomes contributed
by the abnormal gamete is lost, this will result in biparental disomy
(BPD) (the inheritance of one chromosome in a pair from each parent).
If the chromosome contributed by the normal gamete is lost, this will
result in uniparental disomy (UPD) (inheritance of both chromosomes
of a pair from only one parent). BPD theoretically will occur in 2/3
and UPD in 1/3 of the cases, which actually was shown for CPM involv-
ing trisomy 16.10 UPD may be disease causing if an imprinted chromo-
some (chromosome 6, 7, 11, 14, 15, or 20) is involved or through
homozygosity of a gene mutation associated with a recessive disorder.11
In cases where amniocentesis shows normal cytogenetic results after
abnormal NIPT, CPM can only be assumed. Confirmation that CPM is the
origin of an abnormal NIPT result requires cytogenetic analysis of the pla-
centa. If this confirms presence of the chromosome aberration in the pla-
centa, another source for the abnormal NIPT result such as a maternal
malignancy or a maternal constitutional chromosome aberration can be
excluded. In order to prove the placental origin of the trisomy, we col-
lected term placentas in cases in which follow‐up diagnostic testing in
amniotic fluid (AF) was normal or showed very low level mosaicism.2 | MATERIALS AND METHODS
In the time period April 2014 to December 2016, 2073 NIPT were per-
formed at our department in the Erasmus MC Rotterdam. In 15 out of
2073 cases (0.7%), extended NIPT indicated the presence of an autoso-
mal trisomy that was assumed to be present in the placenta: five cases of
trisomy 7, four of trisomy 16, one of trisomy 8, one of trisomy 12, one of
trisomy 20, one of trisomy 21, and two of trisomy 22. In all these cases,
follow‐up amniocentesis was normal except for one case of mosaic tri-
somy 22 that was confirmed in AF. In all cases, the placenta was asked
for in order to confirm that the chromosome aberration, as detected
with NIPT, was present in the placenta. Ten placentas were received.
In all cases, NIPT was performed as part of the Dutch TRIDENT
study, after first trimester screening by the combined test showed
abnormal results.4 This study was approved by the local University
Medical Center Ethics Committees. Follow‐up fetal diagnostic investi-
gations in AF during pregnancy and/or in umbilical cord blood and/or
buccal swab after birth were performed with SNP array (Illumina
Infinium_CytoSNP_850K genotyping array) or FISH on uncultured
amniotic and/or blood or buccal cells and with karyotyping of AF cell
cultures (in situ method).
After birth, placental studies were performed by sampling chori-
onic villi (CV) from two to four different quadrants of the placenta.
Both cell layers of the CV (the cytotrophoblast [CTB] andmesenchymal core [MC]) were separated according to standard tech-
niques.12 In some cases, an umbilical cord biopsy was taken as well.
DNA was isolated, and 50 to 100 ng of DNA was hybridized to the
Illumina Infinium_CytoSNP_850K genotyping array. Whole genome
array profiles were analysed for presence of the trisomy involved by
using Genome Studio (Illumina) and different versions of Nexus Copy
Number (BioDiscovery, versions 7.0 and higher).
The mitotic or meiotic origin of the trisomy was determined using
the B‐allele frequency (BAF) in the mosaic cases as described by
Conlin et al.13 A meiotic origin is seen when the mosaic extra chromo-
some contains a haplotype not present in the other two chromo-
somes, giving rise to two additional BAFs as compared with a mosaic
trisomy of mitotic origin. If in meiotic cases the additional haplotypes
were present near the centromere, this signified the presence of two
different homologues, consistent with a meiosis I (MI) non‐disjunction.
When the additional haplotypes were absent near the centromeres
and present near the telomeres, this was considered to be consistent
with a MII non‐disjunction. In cases without mosaic tissues (cases 4,
7, 8, and 9), but with a 100% discordancy between the karyotypes
of AF or cord blood (100% normal) and placenta (100% trisomy), “dig-
ital mosaics” were made in order to elucidate the meiotic or mitotic
origin. For that, the final reports (text files) produced by Genome Stu-
dio from a 100% trisomic and 100% normal sample from the same
conceptus, containing LogR and BAF values for each probe on the
array, were opened in an Excel file. For each probe, the average of
the LogR and BAF values in both samples was calculated. When this
“digital mosaic” is visualized by uploading in our analysis software
(Nexus), the result will be the same as that of a “real” 50% mosaic.
For validation of this method, we used two cases with a known mitotic
(case 1) and meiotic (case 5) origin of the trisomy based on a mosaic
placental biopsy and for which there was a 100% normal as well as a
100% abnormal placental biopsy available (see Figure S1).
The presence of UPD in the diploid cell line was assumed when the
trisomic chromosome showed runs of homozygosity greater than 10 Mb
in length, demonstrating results of the recombination process in meiosis,
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The presence of UPD in the mosaic trisomy cases was assumed if there
was a mosaic loss of heterozygosity secondary to trisomic rescue of a
meiotic non‐disjunction. In cases 1, 2, 3, and 4 involving trisomy 7, which
is an imprinted chromosome, UPD7 was excluded in AF by performing
SNP array on DNA from AF as well as from parental blood and by com-
paring fetal SNPs with those from both parents. Also in case 9, SNP array
was performed on maternal blood for SNP comparison between mother
and fetus in order to prove the maternal origin of both the trisomy 21
and UPiD21. For comparison of fetal and parental SNPs, we used an
Excel template in which the SNP data is imported for the three individ-
uals, and a score is given for each SNP per parent. If both alleles match
between child and parent, the score is IBS2 (identity by state 2). If only
one allele matches with the parent, the score is IBS1, and if neither allele
matches with the parent, the score is IBS0 (=discordant). Normally, for
each SNP, there is contribution from each parent (no discordance). In
the case of UPD, there is no contribution from one parent for that chro-
mosome, and the score of the SNPs will be IBS0. For example, if the
fetus is BB for a certain SNP, the mother AB and the father AA, then
there is no paternal contribution for this SNP. If this is seen for all SNPs
on a chromosome, this may be interpreted as maternal UPD.
Finally, clinical outcome data such as birth weight, gestational age
at birth, and the presence of congenital malformations were collected.
Small for gestational age was defined as a birthweight below15 p10.3 | RESULTS
3.1 | Prenatal cytogenetic follow‐up studies
The results of SNP array analysis and karyotyping of AF for confirma-
tion of an abnormal NIPT result in nine out of 10 cases are shown in
Table 1. In case 7, the pregnant woman declined diagnostic testing dur-
ing pregnancy. Prenatal studies revealed a normal fetal chromosome
constitution in eight cases, although UPD of a nonimprinted chromo-
some (chromosome 16) was present in one case (case 8 in Table 1). In
a case of trisomy 22 (case 10 in Table 1), AF showed low‐level trisomy
22 mosaicism with UPD22 in the karyotypically normal cell line.
3.2 | Postnatal cytogenetic confirmatory studies
The results of SNP array analyses of the 10 placentas, cord blood in
seven cases (including case 7 who declined invasive testing), and
umbilical cord in cases 5 and 8 are shown in Table 1. In one case (case
10), also FISH was applied to a buccal swab of the newborn.
Firstly, the abnormal NIPT result was confirmed in the placenta in
all cases: at least one biopsy showed the trisomy that was detected
with NIPT. Moreover, in 5/10 cases extra cell lines, that were not
detected prenatally, were found:
1. In 2/10 cases, additional trisomies were detected: in case 2, one
placental biopsy also revealed a mosaic trisomy 13 in addition
to the trisomy 7, and in case 5, an additional trisomy 14 was
found besides the trisomy 12.
2. In 2/10 cases (cases 6 and 9), with a normal BPD result in AF, a
UPD cell line in addition to a BPD cell line, involving thechromosomes 16 (case 6) (Figure 1) and 21 (case 9) (Figure 2)
was found in the placenta.
3. In 1/10 cases (case 10) with a mosaic trisomy 22/UPhD22 in AF,
a BPD22 but no UPD22 cell line was detected in the placenta
(Figure 3).
This means that in three of 10 cases (cases 6, 9, and 10), mosai-
cism for a trisomic cell line and two different “normal” cell lines, one
with a BPD and one with a UPD, was found.
Concerning the origin of the trisomy, based on the BAF profiles, all
cases of trisomy 7 (case 1‐4) were shown to have a mitotic origin,
although a meiosis II origin without recombination formally cannot be
excluded. The additional trisomy 13 in case 2 also was of mitotic origin.
In cases 5, 6, 7, 8, and 10, the BAF patterns in mosaic tissues or based
on digital mosaics were consistent with a meiosis I non‐disjunction
(case 6 in Figure 1). In case 5 with a double trisomy 12 and 14, both tri-
somic cell lines had a meiosis I origin (see also Figure S1). In case 9 with
a 100% trisomy 21 in the CTB of biopsy 3 and a complete isodisomy 21
in the CTB of biopsy 4 (Figure 2), a meiosis II non‐disjunction, without
crossovers is possible, based on SNP analysis (see Figure S2). However,
it is similarly plausible that the trisomy originated postzygotically
through mitotic non‐disjunction or isochromosome formation.3.3 | Clinical outcome
Clinical outcome data are shown inTable 1. In two of 10 cases (cases 2
and 7), the child was small for gestational age (<p10). In two cases
(cases 2 and 6), the pregnancy was complicated by pre‐eclampsia, and
in three cases (cases 6, 7, and 10), children were born prematurely. In
case 8, the child has a complete atrioventricular septum defect (AVSD).4 | DISCUSSION
In this paper, we describe the results of cytogenetic investigations by
SNP array of 10 term placentas that were primarily performed for
cytogenetic confirmation of abnormal results of genome‐wide NIPT
as previously suggested.16 These studies confirm that the abnormal
NIPT results are caused by a placental trisomy, which makes another
potential source like a maternal malignancy fairly unlikely. In almost
half of the cases, at least one of the placenta biopsies was shown to
be chromosomally normal, stressing the importance of analysing more
than one biopsy for confirmation studies.16-18
As can theoretically be expected, in one‐third (two of six) of
meiotic trisomy cases, UPD was found in the diploid AF cells.9
However, in one of these two cases (case 10), a BPD was found in
the normal cell line in the placenta, while UPD was absent in all inves-
tigated biopsies. The reverse was found in two other cases with BPD
in normal AF cells, while trisomy/UPD/BPD mosaicism was found in
the placenta (cases 6 and 9). These mosaics consisting of two different
diploid cell lines besides a trisomic cell line provide evidence that they
originated through different trisomy rescue events during early
embryogenesis in at least two out of three cases (cases 6 and 10). In
one case (case 9), the mosaic trisomy21/UPiD21/BPD21 may have
originated from different trisomic rescues, although a mitotic origin
TABLE 1 Results from prenatal and postnatal cytogenetic studies and clinical follow‐up in 10 cases of abnormal NIPT indicating an autosomal
trisomya
NIPT
Result
Prenatal
Cytogenetics
Postnatal Cytogenetics
Origin Trisomyb
Mosaicism in
Conceptus Clinical OutcomePlacenta Cord blood
Umbilical
cord
1 Tris 7e Amniocentesis:
‐SNP array: normal
‐no UPD7
‐karyo: 46,XX[12]
2 placenta biopsies:
Biopsy 1:
‐CTB normal
‐MC 20% +7/BPD7
Biopsy 2:
‐CTB: 100% + 7
‐MC normal (BPD7)
‐SNP array:
normal
‐no UPD
‐ Mitoticc Trisomy/BPD7 Liveborn at 39 wk, 3182 g,
p20‐p50
No congenital anomalies
Uneventful pregnancy
2 Tris 7 Amniocentesis:
‐SNP array: normal
‐no UPD7
‐karyo: 46,XX[18]
4 placenta biopsies:
Biopsy 1:
‐CTB: 100% + 7
‐MC: normal (BPD7)
Biopsy 2:
CTB and MC: normal
(BPD7)
Biopsy 3:
‐CTB: 90% +7/BPD7
‐MC: 20% + 7/BPD7
Biopsy 4:
‐CTB: 20% + 13/
normal (BPD7)
‐MC: 20% + 7/BPD7
‐SNP array:
normal
‐no UPD
‐ Mitoticc
(both tris 7
and tris 13)
Trisomy/BPD7 Liveborn at 38 1/7 wk, 2470 g,
p5‐p10 (SGA)
No congenital anomalies
Induced delivery due to pre‐
eclampsia
3 Tris 7 Amniocentesis:
‐SNP array: normal
‐no UPD7
‐karyo: 46,XX[30]
4 placenta biopsies:
Biopsy 1:
‐CTB: normal (BPD7)
‐MC: 60% + 7/BPD7
Biopsy 2:
‐CTB: normal (BPD7)
‐MC: 5% + 7/BPD7
Biopsy 3:
‐CTB: normal (BPD7)
‐MC: 90% + 7/BPD7
Biopsy 4:
‐CTB: normal (BPD7)
‐MC: normal (BPD7)
‐ ‐ Mitoticc Trisomy/BPD7 Liveborn at 38 3/7 wk, 3270 g,
p50‐p80
No congenital anomalies
Uneventful pregnancy
4 Tris 7 Amniocentesis:
‐SNP array: normal
‐no UPD7
‐karyo: 46,XX[23]
4 placentabiopsies,
one analysed:
Biopsy 1: CTB and
MC: 100% tris 7
‐ ‐ Mitoticc Trisomy/BPD7 Liveborn at 38 3/7 wk, 2640 g,
p16‐p20
No congenital malformations
5 Tris 12 Amniocentesis:
‐SNP array: normal
‐no UPD12
‐karyo: 46,XX[24]
4 placentabiopsies:
Biopsies 1, 2, and 3:
‐CTB: normal
‐MC: normal
Biopsy 4:
‐CTB: 100% tris 12
and tris 14
‐MC: approximately
15% tris 12 and
tris 14/BPD12
and 14.
‐SNP array:
normal
‐no UPD
‐ SNP
array
normal
‐ no UPD
MI (both tris 12
and tris 14)
Trisomy/
BPD12,14
Liveborn at 40 5/7 wk, 3576 g,
p50
No congenital anomalies
Uneventful pregnancy
6 Tris 16f Amniocentesis:
‐SNP array: normal
‐no UPD16
‐karyo: 46,XY[18]
3 placenta biopsies:
Biopsy 1:
‐CTB:
UPhD16(90%)/
BPD16(10%)
‐MC: UPhD16(50%)/
BPD16(50%)
Biopsy 2:
‐CTB: 100% + 16
‐MC: approximately
20% + 16/BPD16
Biopsy 3:
‐CTB: 80% +16/
UPhD16
‐MC: approximately
40% + 16/BPD16
‐SNP array:
normal
‐no UPD16
‐ MI Trisomy/UPhD/
BPD
Liveborn at 36 2/7 wk, 2510 g,
p20‐p50
No congenital anomalies.
Severe pre‐eclampsia
Caesarean section because of
breech presentation
(Continues)
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TABLE 1 (Continued)
NIPT
Result
Prenatal
Cytogenetics
Postnatal Cytogenetics
Origin Trisomyb
Mosaicism in
Conceptus Clinical OutcomePlacenta Cord blood
Umbilical
cord
7 Tris 16g ‐ 4 placenta biopsies:
‐CTB of 4 biopsies:
100% + 16
‐MC of 1 biopsy:
100% + 16
‐SNP array:
normal
‐no UPD16
‐ MI Trisomy/BPD Liveborn at 34 1/7 wk, 1435 g,
<p5 (IUGR)
No congenital anomalies.
Emergency caesarean section
IUGR from 20 wk of gestation
Good catch‐up growth after
birth
Normal psychomotor
development at 1 y
8 Tris 16 Amniocentesis:
‐SNP array: normal
‐UPhD16
‐karyo 46,XX[21]
4 placentabiopsies:
‐CTB and MC of all 4
biopsies: 100%
trisomy 16
‐SNP array:
normal
‐UPhD16
‐SNP
array:
normal
‐UPhD16
MI Trisomy/UPhD Liveborn, at 38 1/7 wk, 2500 g,
<p16
Pregnancy complicated by
oligohydramnios
Induction of labour
Emergency caesarean section
(nonreassuring CTG and
failure to progress)
Complete AVSD (not detected
by ultrasound)
9 Tris 21 Amniocentesis:
‐SNP array: normal
‐no UPD21
Maternal blood:
SNP array normal
4 placentabiopsies:
Biopsies 1 and 2:
CTB and MC
normal (BPD21)
Biopsy 3:
‐CTB: 100% trisomy
21
‐MC: normal
(BPD21)
Biopsy 4
‐CTB: UPiD21
‐MC: normal
(BPD21)
‐ ‐ MII or mitoticd Trisomy/UPiD/
BPD
Liveborn, 40 4/7 wk, 3370 g,
p20‐p50
No congenital anomalies
Uneventful pregnancy
10 Tris 22 Amniocentesis:
‐SNP array: 10%
+22 or 10%
BPD22
‐UPhD22 in normal
cell line
‐karyo: 46,XY[33]
4 placentabiopsies:
Biopsy 1:
‐CTB: approximately
30% +22/BPD22
‐MC: approximately
50% +22/BPD22
Biopsies 2, 3, and 4:
CTB and MC 100%
tris 22
‐SNP array:
normal
‐UPhD22
‐FISH buccal
swab and cord
blood
(probe:
BCR(22q11)/
ABL(9q34) dual
fusion, Vysis):
normal in 200
nuclei
‐ MI Trisomy/UPhD/
BPD
Liveborn at 31 3/7 wk,
caesarean section, 1160 g,
p10‐p16
No congenital anomalies
Pregnancy complicated by
recurrent vaginal bleeding and
premature labour
Emergency caesarean section
due to premature labour,
breech position, and previous
caesarean section
Hospitalized for 9 wk due to
prematurity
Note. “‐” means: not available.
Abbreviations: AVSD, atrioventricular septum defect; BAF, B‐allele frequency; BPD, biparental disomy; CTB, cytotrophoblast; Karyo, karyotyping; MI, mei-
osis I; MII, meiosis II; MC, mesenchymal core; UPD, uniparental disomy; UPiD, uniparental isodisomy; UPhD, uniparental heterodisomy.
aUnderlined cell lines represent cell lines in the placenta that were not detected prenatally.
bThe origin of the trisomy was determined based on the BAF profiles of the true mosaics in the placenta (cases 1, 2, 3, 5, 6, and 10) or digital mosaics (cases
4, 7, 8, and 9) (see section 2)
cBased on the BAF profiles of cases 1, 2, 3, and 4, a mitotic origin was assumed in the trisomy 7 cases based on the absence of a third haplotype across the
whole chromosome, although a MII origin cannot be excluded. This fits earlier studies.34-36
dAlthough a MII origin is possible, it is similarly plausible that the trisomy arose postzygotically through isochromosome formation or non‐disjunction (see
Figure S2).
ePublished previously: case 2.5 in table S2 of Van Opstal et al.1
fPublished previously: case 2.12 in table S2 of Van Opstal et al.1
gPublished previously: case 2.13 in table S2 of Van Opstal et al.1
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To the best of our knowledge, mosaic trisomy/UPD/BPD as the con-
sequence of different trisomic rescues has only been suggested once
in a patient with Prader‐Willi syndrome.19 In that case, besides a cell
line with maternal UPhD15, there was a normal cell line with a mater-
nal and paternal chromosome 15. As the authors suggested, this
mosaic could only have originated from two independent trisomyrescue events, although trisomic cells were not detected. Trisomic res-
cue has been generally considered to be a single event during the early
cleavage divisions leading to fetal UPD in 1/3 of the cases, which was
actually shown in the present study in AF/cord blood.20 However, our
follow‐up cytogenetic investigations of the placentas revealed that tri-
somic zygote rescue may involve more than one rescue event giving
rise to trisomy/UPD/BPD mosaicism.
FIGURE 1 B‐allele frequency (BAF) plots of chromosome 16 in different tissues of case 6: AF, amniotic fluid; CB, umbilical cord blood; CTB1, 2,
and 3, cytotrophoblast of placental biopsies 1, 2, and 3; MC1, 2, and 3, mesenchymal core of placental biopsies 1, 2, and 3. These BAF profiles
show a meiotic origin of trisomy 16 with additional BAF lines representing genotypes present in the trisomic cell line that are not present in the
diploid cell line. Mosaicism of a trisomy 16 cell line with two different diploid cell lines, one with BPD, and one with UPD was found. AF and CB
both show a normal BAF profile fitting a 100% BPD16. CTB1 and MC1 of placental biopsy 1, both with a normal LogR profile (data not shown),
show UPD16/BPD16 mosaicism of different levels (approximately 90%/10% in CTB and approximately 50%/50% in MC) as shown by a region of
mosaic loss of heterozygosity at the p‐arm telomere. It should be noted that the BAF profile in CTB1 may also fit a low mosaic trisomy 16 of
approximately 10% (with UPD16 in 90%). CTB2 of biopsy 2 shows a 100% trisomy 16. MC2 shows approximately 20% trisomy 16 with BPD 16 in
the diploid cell line based on absence of a mosaic region of homozygosity near the p‐arm telomere. CTB3 of biopsy 3 shows approximately 80%
trisomy 16 with UPD16 in the diploid cell line shown by the altered pattern near the telomere of the p‐arm. MC3 shows approximately 40%
trisomy 16 with BPD16 in the diploid cell line based on absence of a region of homozygosity in the p‐arm. Based on the BAF profile, and as
compared with the BAF profile of MC2, especially at the p‐arm, it cannot be excluded that besides a trisomy 16 and BPD16, also a UPD16 cell line
is present in MC3 [Colour figure can be viewed at wileyonlinelibrary.com]
FIGURE 2 LogR (left) and B‐allele frequency (BAF) profiles of part of the long arm of chromosome 21 in four placental biopsies (1‐4) of case 9.
For each biopsy, cytotrophoblast (CTB) and mesenchymal core (MC) were investigated separately, with the upper plot within biopsies 1 to 4
showing the result of CTB and the lower one of the MC. The LogR plots (left) show a normal diploid result in CTB and MC of biopsies 1, 2, and 4
and of the MC of biopsy 3. In the CTB of biopsy 3, a 100% trisomy 21 was found. The BAF profiles (right) show a normal BPD 21 in CTB and MC
of biopsies 1 and 2 and in the MC of biopsies 3 and 4. A 100% trisomy 21 was found in the CTB of biopsy 3 whereas a UPiD21 was present in the
CTB of biopsy 4, shown by a complete loss of heterozygosity [Colour figure can be viewed at wileyonlinelibrary.com]
6 VAN OPSTAL ET AL.Mosaicism of a cell line with UPD and one with BPD is only rarely
diagnosed in humans. Apart from the case of Horsthemke et al19 men-
tioned above, five other cases of Prader‐Willi syndrome caused bymosaic maternal UPD15/BPD15 can be found in the literature,21-24
one of Silver‐Russell syndrome caused by mosaic maternal UPD7/
BPD7 (case 52 in that publication)25 and two cases of Silver‐Russell
FIGURE 3 The B‐allele frequency (BAF) profiles of chromosome 22 in amniotic fluid (AF) and the mesenchymal core of biopsy 1 (MC1) of case
10. In AF, a low mosaic trisomy 22 of about 10% was found with UPhD in the diploid cell line, as shown by loss of heterozygosity at the telomeric
end of the q‐arm. The UPhD originated from loss of the “green chromosome” as illustrated in the figure on the right; however, it should be noted
that the BAF profile, with a normal LogR, could also fit a low mosaic BPD22 of about 10% with UPD22 in the remaining 90%. In MC1, a mosaic
trisomy 22 was found of about 50% with a BPD22 in the diploid cell line based on absence of a region of homozygosity. This BPD originated
through loss of another trisomic chromosome during early embryogenesis, namely, the pink one, as illustrated in the figure on the right [Colour
figure can be viewed at wileyonlinelibrary.com]
VAN OPSTAL ET AL. 7syndrome caused bymosaic maternal UPD11/BPD11.26,27 However, in
all these cases, the UPD cell line involved a complete isodisomy (UPiD)
suggesting another origin than trisomic rescue. A postfertilization error
with loss of a chromosome followed by endoduplication was suggested
to be the most likely mechanism in these cases.9
As suggested by Izumi et al, the reason for the rarity of detection
of UPD/BPD mosaicism in humans might be the fact that low‐level
mosaicism may not result in an apparent phenotype or because of
the technical difficulty associated with its assessment (ie, methyla-
tion‐sensitive PCR may not be sufficiently sensitive for detecting very
low‐level mosaicism).24 Therefore, they proposed the use of SNP array
as an adjunct to the standard methylation analysis in the evaluation of
Prader‐Willi syndrome, given its ability of detecting low‐level mosai-
cism as well as its capability of identifying regions of homozygosity.
By investigating term placentas, we show evidence that the reason
for its rarity may also be restriction of UPD mosaicism to certain tis-
sues that are usually not investigated. Perhaps like aneuploid cells,
UPD is also involved in CPM with preferential allocation of UPD cells
to the compartment of the placenta in order to “rescue” the fetus. The
fact that trisomic rescue probably occurs during very early embryo-
genesis,28 and since the majority of cells of the early embryo are des-
tined to become the placenta, may explain preferential allocation of
abnormal cell lines to the placenta. On the other hand, presence in
the placenta and absence in AF/blood does not exclude that other tis-
sues are affected. Detection of mosaicism is difficult since routinely
only one tissue (blood) is investigated.27 Therefore, hidden UPD/
BPD mosaicism may be the cause of unexplained disease in cases in
which an imprinted chromosome is involved or through homozygosity
of a mutation in a recessive disease gene. In the present study, only
nonimprinted chromosomes 16, 21, and 22 were involved in the tri-
somy/UPD/BPD mosaic cases, and therefore, no abnormal pheno-
types were to be expected apart from the risk for a recessive
disease. However, in five of 10 cases, the pregnancy was complicated
by the birth of a small for gestational age child, pre‐eclampsia, and/or
prematurity. Moreover, in one case, a child with an atrioventricular
septum defect (AVSD) was born. This confirms the association of
CPM with fetal growth problems, pre‐eclampsia, and/or MCA, at least
in high risk pregnancies,1,29,30 although adverse obstetric outcomeseems to depend on the chromosome involved, level of mosaicism,
and distribution of abnormal cells.31 Moreover, it cannot be excluded
that prematurity in case 10, with low‐level mosaicism trisomy 22 in
AF, may also be the consequence of cryptic fetal trisomy mosaicism
despite normal cytogenetic results in cord blood and buccal swab or
fetal UPD22. Nevertheless, given the increased chance for an
unfavourable obstetric outcome for both fetus and mother, pregnan-
cies with discordant NIPT results should be considered as “high risk”
for adverse obstetric outcome events. Expert fetal ultrasound, fetal
growth surveillance, and high‐level obstetric maternal care should be
offered.
Although UPD/BPD mosaicism is rare in humans, it has frequently
been seen in in vitro fertilization (IVF) embryos.32 It is well‐known that
the first cell cycles following IVF are prone to chromosome instability,
which is characterized by an elevated rate of gains and losses of com-
plete chromosomes or segments of chromosomes per cell cycle
resulting in cell‐to‐cell variability.33 Vanneste et al32 showed, apart
from mosaic whole chromosome and segmental aneuploidy, mosaic
whole chromosome UPD in 9% (2/23) of the embryos, which supports
the findings in the present study. Probably, the placenta reflects the
cytogenetic embryonic chaos and functions as a litter basket for chro-
mosomally abnormal cells.
In all four cases of CPM trisomy 7, the trisomy was shown to have
originated postzygotically, which confirms previous studies.34-36
Although figures on the origin of trisomy 7 are still small, this might indi-
cate that the risk for UPD7 as the consequence of trisomic rescue in
cases of placental trisomy 7 is rather small. However, more studies are
needed to confirm this assumption. The mitotic origin of the trisomy 7
may also explain the normal array results in the CTB of four different
biopsies in case 3. These normal results were not expected since the
NIPT, which investigates cfDNA from the CTB, showed trisomy 7. Pos-
sible explanations are that low‐level mosaicism was present but under
the detection level of the SNP array that we used. Indeed, SNP arrays
are very sensitive for detection of low‐level trisomy mosaicism but not
if of mitotic origin. Another explanation may be placental variation with
CTB at other placental sites that were not investigated, being affected
with trisomy 7.17,18 The reason why the trisomy 12 but not the trisomy
14 was detected with NIPT in case 5 is unclear. Both had a meiotic
8 VAN OPSTAL ET AL.origin, but unfortunately, we could not determine the parental origin
since parental blood was not available. Assuming the same parental ori-
gin, both chromosome aberrations should have been present in the
same cell line, which is supported by the array results of the abnormal
biopsy. However, probably overall higher levels of trisomy 12 than tri-
somy 14were present in the placenta as the result of rescues at a differ-
ent time point: an earlier rescue of trisomy 14 may have led to lower
levels of trisomy 14, especially in that part of the placenta that we did
not investigate. This again stresses the importance of investigating mul-
tiple placental sites as shown in the past.17
Since trisomy/UPD/BPD mosaicism seems to be common in res-
cued trisomic conceptuses of meiotic origin, caution should be taken
when interpreting SNP arrays. As shown by Conlin et al,13 SNP arrays
are very sensitive for detection of low‐level trisomy mosaicism, espe-
cially if the trisomy is of meiotic origin. However, low‐level trisomy
mosaicism (<10%, not showing clear LogR elevation) and low mosaic
UPD may show the same BAF profile. Therefore, both should be con-
sidered when interpreting SNP array results. This means that the BAF
profile of the AF in case 10, that was interpreted as being a case of
low‐level trisomy 22 mosaicism, in fact may also represent a case of
low‐level BPD/UPD mosaicism (10% BPD and 90% UPD).
In conclusion, by investigating term placentas in the context of
confirmatory studies of abnormal NIPT results, we found evidence
that trisomy/UPD/BPD mosaicism as a consequence of more than
one trisomy rescue event during early embryogenesis may be more
common than generally thought. Perhaps it may be the cause of unex-
plained disease if an imprinted chromosome is involved or through
homozygosity of a recessive disease in some unresolved cases. This
argues for storage of placental DNA in cases of newborns presenting
with congenital malformations after NIPT revealed a chromosome
aberration that was not confirmed in AF, so that in case there is no
genetic diagnosis in DNA obtained from blood cells of the newborn,
further studies can be performed. In such cases, genetic studies of
the placenta may reveal chromosomal mosaicism that might also be
present in the child, which may explain the child's phenotype.ACKNOWLEDGEMENTS
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